ESG & BRSR for Pharmaceutical, built around what's material.
ESG isn't one checklist. We focus on the topics that actually move the needle for pharmaceutical companies — then handle the carbon accounting, BRSR reporting and certifications.
The topics that actually matter here
Pharma’s ESG exposure sits in effluent and pharmaceutical waste (including AMR), energy and governance — high-scrutiny topics for regulators and global buyers.
ESG scoring, BRSR performance disclosures and buyer audits all reward the same thing: credible data on your material topics. For pharmaceutical companies, that means:
- Effluents & pharmaceutical waste
- Energy & emissions
- Product quality & safety
- Business ethics & access
The mistake we see: Under-reporting process effluents and the Scope 1 emissions from energy-intensive production.
How we handle ESG for pharmaceutical companies
We pin down the ESG topics that actually matter for your Pharmaceutical operation — and where you stand today.
We build your GHG inventory across Scope 1, 2 and the material Scope 3 categories, from real data — not defaults.
We prepare and file your BRSR (or GRI / chosen framework) disclosures across the nine NGRBC principles.
We get you assurance- and audit-ready — BRSR Core assurance, or GRS / RCS / ISCC where they apply.
Sustainability & ESG partners we work with
Measurement & sustainability work we've delivered
ESG stands on credible measurement. That's our track record — carbon and net-zero projects, independent impact evaluations and international-partner (GIZ) engagements.
Building a Net-Zero, Climate-Resilient Mandede Village
Mandede Village, Taluka Mulashi, Pune district
Single-Use Plastics Value-Chain Assessment
2 cities in Maharashtra & 2 cities in Tamil Nadu
Impact Evaluation of a Decentralized Solid Waste Management Project
16 Bulk Waste Generators across Mumbai & Pune
The Pharmaceutical ESG & BRSR readiness checklist
A one-page checklist of exactly what a Pharmaceutical business should tackle first on ESG — no jargon, no fluff.
- The ESG topics that are actually material to your sector
- Whether BRSR applies to you & what it asks for
- The Scope 1–3 emissions data to start collecting now
Pharmaceutical ESG — questions we get
Straight answers on BRSR, material topics and where to start.
Ask our ESG team →Does my Pharmaceutical business have to do BRSR?
Which ESG topics matter most for Pharmaceutical?
Where should a Pharmaceutical company start?
Does Social Lab support Pharmaceutical companies?
Keep exploring ESG for Pharmaceutical
Two ways forward
Whether you're scoping ESG for your Pharmaceutical business or ready to hand it over.
Not sure where your ESG risk really sits?
Start with a materiality read — the topics that matter and where you stand — before any report is written.
Get an ESG materiality read →Hand your ESG & BRSR to a specialist team
Materiality to assurance, managed end-to-end — carbon footprint, BRSR filing and certifications.
Talk to an ESG expert →Latest thinking on this
ESG & BRSRBRSR Reporting Explained: A Practical Guide for Listed CompaniesWhat BRSR is, why SEBI mandated it, how the three sections and nine NGRBC principles work, and what listed companies must disclose to stay compliant and credible.ESG & BRSRIs BRSR Applicable to Your Company? Understanding Scope and BRSR CoreFind out whether BRSR applies to your business, what BRSR Core adds, how assurance works, and how value-chain disclosure is widening the reporting net to suppliers.
ESG & BRSRBuilding a Corporate Carbon Footprint: Scope 1, 2 and 3 Emissions ExplainedA practical guide to measuring your organisational carbon footprint using the GHG Protocol, from direct emissions to the tricky Scope 3 value chain and its 15 categories.ESG, BRSR and net-zero for pharmaceutical companies — handled.
We start with what's material to your sector and run it end to end. Book a quick ESG materiality read.
Or call +91 77589 17508 · [email protected]